Saturday 17 October 2026
Export VNRX’s income statement to Excel — free account
VolitionRX Limited
VNRX Healthcare Medical Devices
VolitionRX Limited’s revenue for fiscal 2025 (year ended December 2025) was $1.7 million, up 40.0% from fiscal 2024. In the quarter to June 2026, revenue fell 1.97%, EPS grew 29.2%, free cash flow grew 18.6% and total debt rose 7.56%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
0.18
0.01
−5.26%
Follow VNRX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
5.03 | 11.16 | 16.08 | 49.99 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(2.40) | (5.21) | (5.06) | (20.27) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
8.37 | 14.44 | 21.73 | 57.05 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.05) | (1.72) | (1.91) | (4.28) | |
EV/FCF |
(1.03) | (1.69) | (1.87) | (4.18) | |
Quick Ratio |
0.23 | 0.25 | 0.12 | 0.04 | |
Current Ratio |
0.30 | 0.33 | 0.17 | 0.12 | |
Net Debt/EBITDA |
(2.30) | (1.72) | (2.65) | (2.52) | |
Debt/Assets |
132.45% | 123.84% | 157.70% | 164.35% | |
Debt/Equity |
(0.33) | (0.34) | (0.31) | (0.29) | |
Asset Turnover |
0.29 | 0.28 | 0.21 | 0.15 | |
Operating CF/Net income |
0.70 | 0.79 | 0.88 | 0.68 | |
Capex/Depreciation |
0.00 | (0.01) | (0.01) | 0.00 | |
Interest Coverage |
(5.61) | (42.52) | (28.61) | (35.47) | |
Research and Development Expense of Revenue |
451.64% | 289.54% | 552.06% | 364.40% | |
Selling, General and Administrative Expense of Revenue |
690.74% | 353.44% | 625.79% | 548.76% | |
Intangible Assets out of Total Assets |
0.04 | 0.04 | 0.05 | 0.05 | |
Share Based Compensation of Revenue |
59.69% | 22.84% | (29.73%) | 97.11% | |
Graham Net Nets |
(3.05) | (1.38) | (1.46) | (0.56) | |
Graham Number |
17.75 | 21.32 | 25.68 | 26.22 | |
Earnings Yield |
(282.96%) | (104.25%) | (84.62%) | (33.82%) | |
Free Cash Flow Yield |
(160.86%) | (76.49%) | (72.25%) | (27.28%) | |
Revenue per Share |
0.04 | 0.14 | 0.08 | 0.12 | |
Operating CF per Share |
(0.56) | (0.77) | (1.03) | (0.67) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.56) | (0.77) | (1.03) | (0.67) | |
Cash per Share |
0.30 | 0.45 | 0.21 | 0.04 | |
Shareholders Equity per Share |
(3.66) | (4.85) | (6.66) | (6.64) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(3.66) | (4.85) | (6.66) | (6.64) | |
Free Cash Flow |
(5.16) | (5.29) | (5.50) | (3.63) | |
Working Capital |
(9.40) | (9.05) | (10.17) | (10.09) | |
Capital Expenditures |
0.00 | (0.01) | (0.01) | 0.00 | |
Net Current Asset Value |
(37.75) | (37.88) | (40.43) | (41.07) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.02 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.23 | 0.22 | 0.21 | 0.31 | |
Average Payables |
2.96 | 3.37 | 2.84 | 2.80 | |
Average Assets |
8.50 | 8.78 | 8.15 | 9.56 | |
Average Common Equity |
(33.32) | (31.19) | (30.85) | (29.29) |
Columns are period end dates